Potential role of abciximab in ischemic cerebrovascular disease

American Journal of Cardiology

Volumn 85, Issue 8 SUPPL. 1, 2000, Pages 47-51

  Winkley, James M ^a   Adams Jr , Harold P ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DANAPAROID; FIBRINOLYTIC AGENT; HEPARIN; PROUROKINASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ANTICOAGULANT THERAPY; ARTICLE; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; PRIORITY JOURNAL; RADIODIAGNOSIS; TREATMENT OUTCOME;

EID: 0034720136     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00878-X     Document Type: Article

References (30)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
2. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
3. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-2118.
4. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-1251.
5. Clark W.M., Wissman S., Albers G.W., Jhamandas J.H., Madden K.P., Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke . JAMA. 282:1999;2019-2026.
6. Duke R.J., Bloch R.F., Turpie A.G., Trebilcock R., Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke a randomized controlled trial . Ann Intern Med. 105:1986;825-828.
7. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
8. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998;279:1265-1272.
9. del Zoppo G.J., Higashida R.T., Furlan A.J., Pessin M.S., Rowley H.A., Gent M. PROACT a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke: Prolyse in Acute Cerebral Thromboembolism . Stroke. 29:1998;4-11.
10. Furlan A., Higashida R., Wechsler L., Gent M., Rowley H., Kase C., Pessin M., Ahuja A., Callahan F., Clark W.M., Silver F., Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism . JAMA. 282:1999;2003-2011.
11. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641-1649.
12. Neumann F.J., Blasini R., Schmitt C., Alt E., Dirschinger J., Gawaz M., Kastrati A., Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 98:1998;2695-2701.
13. Kaku S., Umemura K., Mizuno A., Yano S., Suzuki K., Kawasaki T., Nakashima M. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis. Eur J Pharmacol. 345:1998;185-192.
14. Choudhri T.F., Hoh B.L., Zerwes H.G., Prestigiacomo C.J., Kim S.C., Connolly E.S. Jr, Kottirsch G., Pinsky D.J. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest. 102:1998;1301-1310.
15. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: the EPIC Investigation. N Engl J Med 1994;330:956-961.
16. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
17. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-1435.
18. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial: the TIMI 14 Investigators. Circulation 1999;21:2720-2732.
19. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
20. Califf R.M. Glycoprotein IIb/IIIa blockade and thrombolytics early lessons from the SPEED and GUSTO IV trials . Am Heart J. 138:1999;S12-S15.
21. Wallace R.C., Furlan A.J., Moliterno D.J., Stevens G.H., Masaryk T.J., Perl J. Basilar artery rethrombosis successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor . Am J Neuroradiol. 7:1997;1257-1260.
22. Cecena F.A., Hoelzinger D.H., Miller J.A., Abu-Shakra S. The platelet IIb/IIIa inhibitor abciximab as adjunctive therapy in carotid stenting of potential thrombotic lesions. J Intervent Cardiol. 12:1999;355-361.
23. Okada Y., Yamaguchi T., Minematsu K., Miyashita T., Sawada T., Sadoshima S., Fujishima M., Omae T. Hemorrhagic transformation in cerebral embolism. Stroke. 20:1989;598-603.
24. van der Worp H.B., Kappelle L.J. Complications of acute ischaemic stroke. Cerebrovasc Dis. 8:1998;124-132.
25. Multicentre Acute Stroke Trial - Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-1514.
26. Donnan G.A., Davis S.M., Chambers B.R., Gates P.C., Hankey G.J., McNeil J.J., Rosen D., Stewart-Wynne E.G., Tuck R.R. Trials of streptokinase in severe acute ischaemic stroke. Lancet. 345:1995;578-579.
27. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G, Leys D, Amarenco P, Bogaert M. Termination of trial of streptokinase in severe acute ischaemic stroke: MAST Study Group (abstract). Lancet 1995;345:57.
28. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000;31:601-609.
29. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996;276:961-966.
30. Clark W.M., Wissman S., Albers G.W., Jhamandas J.H., Madden K.P., Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. JAMA. 282:1999;2019-2026.